Abstract
Depression and anxiety disorders are common in Cushing’s syndrome (CS); mania and psychosis may also occur. Use screening tools to identify psychiatric symptoms and refer for a proper diagnosis. Symptoms may improve after normalization of cortisol levels, so this is the first step in patients with active CS. Provide patients in remission with usual psychiatric care (i.e. psychological, psychosocial and/or pharmacological therapy) to resolve symptoms and improve health-related quality of life, and continue long-term monitoring.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Santos A, Resmini E, Pascual JC, et al. Psychiatric symptoms in patients with Cushing’s syndrome: prevalence, diagnosis and management. Drugs. 2017;77(8):829–42.
Sonino N, Fava GA. Psychiatric disorders associated with Cushing’s syndrome: epidemiology, pathophysiology and treatment. CNS Drugs. 2001;15:361–73.
Loosen PT, Chambliss B, de Bold CR, et al. Psychiatric phenomenology in Cushing’s disease. Pharmacopsychiatry. 1992;25:192–8.
Kelly WF. Psychiatric aspects of Cushing’s syndrome. Q J Med. 1996;89:543–51.
Dorn LD, Burgess ES, Friedman TC, et al. The longitudinal course of psychopathology in Cushing’s syndrome after correction of hypercortisolism. J Clin Endocrinol Metab. 1997;82:912–9.
Tiemensma J, Biermasz NR, Middelkoop HA, et al. Increased prevalence of psychopathology and maladaptive personality traits, after long-term cure of Cushing’s disease. J Clin Endocrinol Metab. 2010;95:129–41.
National Institute for Health and Care Excellence. Common mental health problems: identification and pathways to care (CG123). Manchester: NICE; 2011.
Pivonello R, Simeoli C, De Martino MC, et al. Neuropsychiatric disorders in Cushing’s syndrome. Front Neurosci. 2015;9:129.
Starkman MN. Neuropsychiatric findings in Cushing’s syndrome and exogenous glucocorticoid administration. Endocrinol Metab Clin N Am. 2013;42:477–88.
Nieman LK, Biller BM, Findling JW, et al. Treatment of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:2807–31.
Jeffcoate WJ, Silverstone JT, Edwards CR, et al. Psychiatric manifestations of Cushing’s syndrome: response to lowering of plasma cortisol. Q J Med. 1979;48:465–72.
Bratek A, Kozmin-Burzynska A, Gorniak E, et al. Psychatric disorders associated with Cushing’s syndrome. Psychiatr Danub. 2015;27:S339–43.
Gorniak M, Rybakowski J. Paranoid syndrome in the course of Cushing’s disease. Post Psychiatr Neurol. 2005;14:18–20.
Tang A, O’Sullivan AJ, Diamond T, et al. Psychiatric symptoms as a clinical presentation of Cushing’s syndrome. Ann Gen Psychiatry. 2013;12:23.
Korlym® (mifepristone): US Prescribing Information. Menlo Park: Corcept Therapeutics Inc.; 2017.
Fleseriu M, Biller BM, Findling JW, et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s syndrome. J Clin Endocrinol Metab. 2012;97:2039–49.
Chu JW, Matthias DF, Belanoff J, et al. Successful long-term treatment of refractory Cushing’s disease with high-dose mifepristone (RU 486). J Clin Endocrinol Metab. 2001;86:3568–73.
van der Lely AJ, Foeken K, Van Der Mast RC, et al. Rapid reversal of acute psychosis in the Cushing syndrome with the cortisol-receptor antagonist mifepristone (RU 486). Ann Intern Med. 1991;114:143–4.
Castinetti F, Fassnacht M, Johanssen S, et al. Merits and pitfalls of mifepristone in Cushing’s syndrome. Eur J Endocrinol. 2009;160:1003–10.
Bilgin YM, van der Wiel HE, Fischer HR, et al. Treatment of severe psychosis due to ectopic Cushing’s syndrome. J Endocrinol Invest. 2007;30:776–9.
National Collaborating Centre for Mental Health (UK). Depression in adults with a chronic physical health problem: treatment and management. Leicester: The British Psychological Society; 2010.
National Collaborating Centre for Mental Health (UK). Generalised anxiety disorder in adults: The NICE guideline on management in primary, secondary and community care (CG113). Leicester: The British Pyschological Society; 2011.
National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder in adults: management (CG113). Manchester: National Institute for Health and Care Excellence; 2011.
Gotch PM. Cushing’s syndrome from the patient perspective. Endocrinol Metab Clin N Am. 1994;23:607–17.
Webb SM, Crespo I, Santos A, et al. Management of endocrine disease: quality of life tools for the management of pituitary disease. Eur J Endocrinol. 2017;177(1):R13–26.
Author information
Authors and Affiliations
Consortia
Ethics declarations
The article was adapted from Drugs 2017;77(8):829–42 by employees of Adis/Springer and was not supported by any external funding.
Rights and permissions
About this article
Cite this article
Adis Medical Writers. Manage psychiatric symptoms in Cushing’s syndrome by controlling cortisol levels and usual psychiatric therapy. Drugs Ther Perspect 33, 529–534 (2017). https://doi.org/10.1007/s40267-017-0444-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40267-017-0444-4